PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 19, 2013Expert Opinion on Therapeutic Targets79 citationsOpen Access

Targeting Cdc42 in cancer

View Full Paper
LALuis E. Arias‐RomeroJCJonathan Chernoff

Key Points

Key points are not available for this paper at this time.

Abstract

INTRODUCTION: The Rho GTPases are a family of proteins that control fundamental cellular processes in response to extracellular stimuli and internal programs. Rho GTPases function as molecular switches in which the GTP-bound proteins are active and GDP-bound proteins are inactive. This article will focus on one Rho family member, Cdc42, which is overexpressed in a number of human cancers, and which might provide new therapeutic targets in malignancies. AREAS COVERED: In this article, the key regulators and effectors of Cdc42 and their molecular alterations are described. The complex interactions between the signaling cascades regulated by Cdc42 are also analyzed. EXPERT OPINION: While mutations in Cdc42 have not been reported in human cancer, aberrant expression of Cdc42 has been reported in a variety of tumor types and in some instances has been correlated with poor prognosis. Recently, it has been shown that Cdc42 activation by oncogenic Ras is crucial for Ras-mediated tumorigenesis, suggesting that targeting Cdc42 or its effectors might be useful in tumors harboring activating Ras mutations.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Arias‐Romero et al. (2013) studied this question.

synapsesocial.com/papers/6a7a1ad5a861e9f5993270b6https://doi.org/10.1517/14728222.2013.828037
Ask AI
Helpful
Bookmark
Share
View Full Paper